Biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) reported on Monday the start of treatment of the first patient in China under the Phase I registrational study of BLU-667 in collaboration with its partner Blueprint Medicines.
This clinical trial of of BLU-667 is a part of the partnership's ongoing, global Phase I ARROW trial that is designed to evaluate its overall response rate (ORR), duration of response, pharmacokinetics, pharmacodynamics and safety in patients with RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other advanced solid tumors.
NSCLC reportedly accounts for 80-85% of all lung cancers and RET fusions occur in approximately 1-2% of all NSCLC cases. Thyroid cancer is the most common type of endocrine cancer and has shown rising incidence rates in recent years.
According to the company, BLU-667 is an investigational, once-daily oral precision therapy specifically designed for highly potent and selective targeting of oncogenic RET alterations.
In conjunction, the updated results from the company's ARROW clinical trial of BLU-667 showed durable anti-tumor activity regardless of RET-altered tumor type and was well-tolerated. These patients with RET-fusion NSCLC and RET-mutant MTC received a starting dose of 400mg once daily, which is the recommended Phase 2 dose.
Across all patients, BLU-667 was well-tolerated and most adverse events reported by investigators were Grade 1 or 2, concluded the company.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review